Have you looked into how Exelixis (EXEL) performed internationally during the quarter ending June 2024? Considering the widespread global presence of this drug developer, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must understand a comp ...